A new hand-held device that uses lasers and sound waves may change the way doctors treat and diagnose melanoma, according to a team of researchers from Washington University in St. Louis.
The instrument, described in a paper published today in The Optical Society’s (OSA) journal Optics Letters, is the first that can be used directly on a patient and accurately measure how deep a melanoma tumor extends into the skin, providing valuable information for treatment, diagnosis or prognosis.
Melanoma is the fifth most common cancer type in the United States, and incidence rates are rising faster than those of any other cancer. It’s also the deadliest form of skin cancer, causing more than 75 percent of skin-cancer deaths.
The thicker the melanoma tumor, the more likely it will spread and the deadlier it becomes, says dermatologist Lynn Cornelius, one of the study’s coauthors. Being able to measure the depth of the tumor in vivo enables doctors to determine prognoses more accurately—potentially at the time of initial evaluation—and plan treatments and surgeries accordingly.
The problem is that current methods can’t directly measure a patient’s tumor very well. Because skin scatters light, high-resolution optical techniques don’t reach deep enough. “None are really sufficient to provide the two to four millimeter penetration that’s at least required for melanoma diagnosis, prognosis or surgical planning,” says engineer Lihong Wang, another coauthor on the Optics Letters paper.
Researchers have tried other methods, but they aren’t much better. High-frequency ultrasound doesn’t have enough image contrast, and magnetic resonance imaging and positron emission tomography have insufficient resolution and require expensive and bulky instruments.
“Any type of tissue diagnosis at this point in time requires taking tissue out of the person and processing it and looking at it under the microscope,” Cornelius says.
But because taking a biopsy often only involves the removal of a part of a tumor—when it’s in a cosmetically sensitive area, for instance—provisional measurements of the tumor depth are not always reliable. If, at the time of excision, the surgeon finds that the tumor goes deeper than initially thought, the patient may need yet another surgery.
Recently, researchers including Wang have applied an approach called photoacoustic microscopy, which can accurately measure melanoma tumors directly on a patient’s skin—thus allowing doctors to avoid uncertainty in some circumstances.
The technique relies on the photoacoustic effect, in which light is converted into vibrations. In the case of the new device, a laser beam shines into the skin at the site of a tumor. Melanin, the skin pigment that’s also in tumors, absorbs the light, whose energy is transferred into high-frequency acoustic waves. Unlike light, acoustic waves don’t scatter as much when traveling through skin. Tumor cells will produce more melanin than the surrounding healthy skin cells, and as a result, the acoustic waves can be used to map the entire tumor with high resolution. The device has a detector that can then turn the acoustic signal into a three-dimensional image on a screen.
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- Family History of Melanoma Increases Skin Ca Riskon July 22, 2019 at 10:28 am
Patients with a family history of melanoma were at significantly greater risk for developing melanoma and other skin cancers, especially on the trunk and extremities, an analysis of prospective ... […]
- CXCL12 loaded-dermal filler captures CXCR4 expressing melanoma circulating tumor cellson July 22, 2019 at 2:29 am
Development of distant metastasis relies on interactions between cancer and stromal cells. CXCL12, also known as stromal-derived factor 1α (SDF-1α), is a major chemokine constitutively secreted in ... […]
- Uveal melanoma patient registry plannedon July 19, 2019 at 8:53 am
Immunocore and Pulse Infoframe announced a partnership to support a global patient registry in uveal melanoma, according to a press release. Institutions from the United States, the United Kingdom and ... […]
- As UK melanoma rates soar, what are the signs, symptoms and risk factors of skin cancer ?on July 18, 2019 at 5:25 pm
Skin cancer rates have soared by 45% in the UK over the last decade, Cancer Research UK has warned. Melanoma incidences rose in men by 53% in 2014-2016 and diagnoses in 25-49 year olds rose by 78% in ... […]
- Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targetson July 18, 2019 at 2:13 am
Mucosal melanoma arises from melanocytes that reside in a range of internal epithelial tissues of ectodermal origin. The oral cavity, nose and paranasal sinuses, genital tract, and anorectal region ... […]
- Detailed Review of Tebentafusp (IMCgp100) in Metastatic Uveal Melanoma Published in Issue of Cancerson July 16, 2019 at 6:43 am
Before it's here, it's on the Bloomberg Terminal. ... […]
- Survival advantage suggested in responders to immunotherapy for uveal melanomaon July 15, 2019 at 2:25 pm
A possible survival advantage in patients with metastatic uveal melanoma who respond to treatment with pembrolizumab is suggested in a study of the anti-PD-1 monoclonal antibody as immunotherapy for ... […]
- Melanoma Scanner Market 2019| Size, Industry Share, Approaches and Forecast By 2024 - Market Research Engineon July 15, 2019 at 11:52 am
Jul 15, 2019 (Heraldkeepers) -- New York, July 15, 2019: The global Melanoma Scanner market is segregated on the basis of Product Type as Standalone Melanoma Scanner and Handheld Melanoma Scanner. ... […]
- United States Non-Melanoma Skin Cancer Market Study 2019: Analyses & Forecasts Through 2014-2024 - ResearchAndMarkets.comon July 11, 2019 at 7:49 am
The "US Non-Melanoma Skin Cancer Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering. US Non-Melanoma Skin Cancer Market and Competitive Landscape ... […]
- Newly Published Study Establishes Evidence-Based Population for Clinical Use of DecisionDx-Melanoma in Patients With Thin Cutaneous Melanoma Tumorson July 11, 2019 at 4:01 am
Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of a study that ... […]
via Bing News